Related Experiment Videos
Pelvic perfusion hyperthermia for advanced pelvic malignancies
The Japanese Journal of Surgery
|January 1, 1985
Summary
Pelvic perfusion hyperthermia (PPH) effectively treats gynecologic cancers by delivering chemotherapy directly to tumors. This innovative cancer therapy shows promising results with minimal side effects and significant tumor reduction.
Area of Science:
- Oncology
- Gynecologic Oncology
- Hyperthermia Therapy
Background:
- Malignant gynecologic diseases in the pelvis present treatment challenges.
- Optimizing chemotherapy delivery and minimizing systemic toxicity are crucial.
- Hyperthermia offers a potential adjunct to conventional cancer treatments.
Observation:
- Pelvic perfusion hyperthermia (PPH) was administered for four hours in patients with pelvic gynecologic malignancies.
- Continuous monitoring tracked chemotherapeutic drug concentrations in blood, tissues, and the perfusion circuit.
- Patient core temperature was maintained below 40°C, while tumor temperatures ranged from 41.8°C to 42.7°C for over three hours.
Findings:
- Chemotherapeutic drugs were effectively localized within the tumor-bearing pelvic region.
- Systemic drug leakage was minimal, resulting in no discernible systemic side effects.
- Significant tumor response was observed, including an 80% reduction in size in one patient and complete tumor regression in another.
Implications:
- PPH demonstrates potential as a valuable adjunct to standard cancer therapy for pelvic tumors.
- This technique warrants further investigation for its efficacy and safety in gynecologic oncology.
- Optimized drug delivery and localized hyperthermia may improve treatment outcomes for advanced pelvic cancers.